26results about How to "Reduce apoptosis" patented technology

This invention discloses a method for preparing HVC NPs for the diagnosis and treatment of Parkinson's disease and their applications. The probe HV in the HVC NPs responds to H2O2 and viscosity, utilizing near-infrared fluorescence imaging capabilities to achieve real-time monitoring of Parkinson's disease biomarkers, helping us better understand the occurrence and development of Parkinson's disease. With the assistance of RVG29, the HVC NPs effectively cross the blood-brain barrier. The curcumin within them can reduce cell apoptosis, lower oxidative stress levels, scavenge excess reactive oxygen species, combat inflammation, and reduce α-synuclein aggregation, demonstrating effective anti-Parkinson's disease effects at the cellular and experimental animal levels. This nanomaterial provides a new strategy for integrated research on the diagnosis and treatment of Parkinson's disease.

This invention belongs to the field of medical technology, specifically relating to the application of mitochondrial transplantation to regulate the immune-metabolic network in the treatment of myocardial dysfunction after cardiac arrest. The mitochondrial transplantation is performed within 0.5-2 hours after the restoration of spontaneous cardiac circulation. This technical solution, through multi-omics integrated analysis, proposes that mitochondrial transplantation exerts a cardioprotective effect by regulating the immune-metabolic-mitochondrial triaxial synergistic network, providing a new research direction for the precision treatment of myocardial dysfunction after cardiac arrest.

This invention relates to the field of cell biology, specifically to a co-culture cell model and method for primary glial cells and neurons. The method for co-culturing primary glial cells and neurons provided by this invention includes the following steps: a mixture of primary glial cells and neurons is seeded into a first co-culture medium for pre-culture; the medium is discarded and the cells are washed; a second co-culture medium is added for a first-stage culture; after the first-stage culture, a second-stage culture is performed; the medium used in the second-stage culture is a third co-culture medium supplemented with macrophage colony-stimulating factor; after the second-stage culture, a third-stage culture is performed; the medium used in the third-stage culture is the second co-culture medium; in the obtained co-culture cell model, microglia are differentiated and mature, and are in a quiescent state, thus obtaining a primary glial cell and neuron co-culture model.

The application provides application of a CSRNP1 inhibitor in preparation of a medicine for treating liver ischemia-reperfusion injury. The application further clarifies a molecular mechanism in which CSRNP1 improves hepatocyte injury by targeting a MAPK signaling pathway mediated cell apoptosis in the process of ischemia-reperfusion, and provides a new treatment strategy for reducing ischemia-reperfusion injury in a liver surgery process, by deeply analyzing expression changes of CSRNP1 in the process of liver ischemia-reperfusion and correlation between the expression changes and ischemia-reperfusion injury caused by a liver surgery.

The invention relates to the field of A61K8 / 00, in particular to a composition for promoting rapid growth of hair and application of the composition. By adopting the specific amino acid composition, the physiological active component, the plant source glucoside, the protein hydrolysate, the diguanide tetraphosphate and the anti-inflammatory agent, through the synergistic effect of all the active raw materials, the provided composition for promoting rapid growth of hair is added to prepare hair washing and hair care products, and the hair washing and hair care products are applied to people with alopecia to use or treat the alopecia. Hair stem cell stimulation and rapid hair follicle regeneration are effectively induced, scalp aging is prevented, the treatment effect is remarkable, and no obvious side effect exists.

The application discloses a normal-temperature extracorporeal perfusion solution for maintaining liver activity, and mainly relates to the technical field of organ perfusion. The normal-temperature extracorporeal perfusion solution for maintaining liver activity comprises the following components: high-efficiency oxygen-carrying carriers HBOC, energy metabolism components, hormones and growth factors, antioxidant components, microcirculation protection factors, HEPES buffer, inorganic salts, amino acids and vitamins. Compared with the prior art, the perfusion solution can make an isolated liver maintain a high bile secretion amount and stable portal vein pressure during normal-temperature perfusion, reduce the rising range of ALT and AST, reduce hepatocyte apoptosis and protect the structural integrity of mitochondria, thereby effectively reducing hepatocyte damage, maintaining liver activity, and being suitable for isolated liver preservation, pre-transplantation evaluation and related extracorporeal experiments.

This invention belongs to the field of microbial application technology, specifically relating to a method for preparing fermented *Lactobacillus limnoxicamis* extracellular vesicles, the product, and its applications, particularly the application of these fermented *Lactobacillus limnoxicamis* extracellular vesicles and their lyophilized formulations in the preparation of products with antioxidant or anti-aging effects. In this invention, *Lactobacillus limnoxicamis* is inoculated into a modified extracellular vesicle induction medium for fermentation. After culture, a two-stage solid-liquid separation is performed, and the supernatant is collected to obtain the extracellular vesicle processing solution. This solution is purified using a capillary electrophoresis system, and the positive extreme liquid is collected and filtered to obtain the purified product of fermented *Lactobacillus limnoxicamis* extracellular vesicles. The extracellular vesicles derived from fermented *Lactobacillus limnoxicamis* prepared by this invention can effectively scavenge free radicals. Somatic cell experiments have demonstrated its excellent anti-aging properties, and the transformation and application research of *Lactobacillus* extracellular vesicles has explored its development potential in the field of anti-aging products.

This invention belongs to the field of biomedicine, and specifically relates to the application of FeTMPyP in the preparation of drugs to alleviate ovarian toxicity. This application addresses the issue that combined exposure to MC-LR and NaNO₂ significantly induces nitrification stress in mouse ovaries, leading to follicular barrier disruption and ovarian reproductive endocrine dysfunction. FeTMPyP was selected as an intervention agent, which effectively alleviated nitrification stress induced by combined exposure to MC-LR and NaNO₂ in mouse ovaries, and improved sex hormone disorders, estrous cycle irregularities, and follicular atresia caused by the combined exposure to these two toxins. Simultaneously, it restored the fertility of mice, indicating that FeTMPyP intervention can alleviate ovarian toxicity induced by combined exposure to MC-LR and NaNO₂ in mice. This invention can be used to prepare drugs to prevent and treat diseases related to ovarian toxicity caused by environmental toxin exposure in mice, providing a new approach for the early identification and targeted intervention of ovarian-related diseases.

The invention discloses an application of a neuron-derived neurotrophic factor NDNF in promotion of regenerative repair and functional reconstruction of an injured heart, particularly relates to an application of the NDNF in a medicine for treating or improving the injured heart, a recombinant vector and a medicine, and belongs to the technical field of biological medicines. The invention provides application of NDNF in promotion of regenerative repair and functional reconstruction of damaged heart. The invention proves that the medicine prepared from the NDNF can be used for treating or improving the insufficiency and inflammation of the damaged heart, and particularly has a good treatment effect on the damaged heart caused by myocardial infarction, and the treatment effect specifically comprises the effect of reducing myocardial cell apoptosis and inflammation after myocardial infarction and the effect of inhibiting myocardial cell pathological hypertrophy after myocardial infarction due to overexpression of the NDNF. In addition, overexpression of the NDNF can also promote proliferation of myocardial cells after myocardial infarction.

The application belongs to the technical field of medicine, and particularly relates to application of curculigoside in prevention and treatment of intervertebral disc degeneration. The application is for development of a non-surgical scheme for effectively treating IDD. The application finds that CUR (curculigoside) can reduce occurrence of cell apoptosis in vivo by inhibiting phosphorylation of STAT3 and up-regulating expression of BMAL1 (brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1 gene), thereby reducing IVDD (intervertebral disc degeneration). It is indicated that CUR plays an important role in regulating IVDD progression, can alleviate progression of IVDD by up-regulating expression of BMAL1, and is expected to be used as a promising drug for treating IVDD. The application not only develops a new use of CUR, but also provides a new drug use strategy for prevention and treatment of IVDD.

The application discloses a kind of polypeptide, polypeptide extraction and purification method with river toad as raw material and application thereof, belong to the field of bioactive peptide, its amino acid sequence is FPGGPGAK, and preparation method and application in the field of cosmetics are also disclosed.The polypeptide disclosed in the application, polypeptide extraction and purification method with river toad as raw material and application thereof are extracted, purified and screened by treating river toad skin, and the central peptide segment playing a photoprotection role is used in cosmetics.

The invention discloses an application of a benzo-aza derivative in preparation of a medicine for preventing or treating atherosclerosis, the benzo-aza derivative is a compound with a chemical structure as shown in a formula I, or a pharmaceutically acceptable salt, a precursor or a metabolite of the compound, and in the formula I, X is halogen or H. The traditional Chinese medicine composition has the technical effects that the plaque stabilizing effect is obvious, the plaque composition is improved, the necrosis core area in the plaque is reduced, the total plaque load can be effectively reduced, the lesion progress is delayed / reversed, the dependence on lipid reduction is avoided, the treatment blank is filled, a brand new plaque stabilizing treatment strategy is provided, and the clinical problem of residual cardiovascular risks is expected to be solved. The safety is good, the organ specificity is high, and the whole body toxicity is low. The invention provides a new treatment normal form, new use of old medicines and large clinical transformation potential, and can be used as a supplement and enhancement of a basic therapy (such as statin lipid reduction) to form a combined treatment scheme of lipid reduction and spot stabilization, thereby realizing multi-channel cooperative control of atherosclerosis.

The invention relates to the technical field of medicines, and discloses application of gastrodin in preparation of a medicine for preventing and treating radioactive liver injury, and the radioactive liver injury is liver injury caused by ionizing radiation exposure. The gastrodin is found to be capable of effectively intervening a specific mechanism of the radiation-induced liver injury, so that the death rate of mice with the radiation-induced liver injury is remarkably reduced, meanwhile, the core pathological characteristics of hepatic vein occlusion and hepatic fibrosis of the radiation-induced liver injury are reversed, and the radiation-induced liver injury is treated in a more targeted manner. On the other hand, gastrodin is used before radiation exposure, so that serious radioactive liver injury after radiation exposure can be prevented.

The invention provides an application of a xanthoceras sorbifolia bunge extract in preparation of a medicine for preventing and / or treating microwave radiation injury. The xanthoceras sorbifolia bunge seed kernel extract is residues obtained after xanthoceras sorbifolia bunge seed kernels are subjected to oil extraction. Experimental results show that the shiny-leaved yellowhorn seed kernel extract has a protection effect on microwave radiation damage, specifically, the shiny-leaved yellowhorn seed kernel extract can improve the survival rate of nerves, myocardium and germ cells after microwave radiation, reduce cell apoptosis, reduce ROS and MDA content increase, enhance the activity of SOD, GPX and CAT and remove hydroxyl radicals in vitro, and the shiny-leaved yellowhorn seed kernel extract is non-toxic to the cells and has a good application prospect. And new products and ideas are provided for the expansion of medicines for preventing and / or treating microwave radiation injury.

The application relates to the fields of biotechnology and targeted therapy, and particularly relates to a recombinant construct, a CAR-T cell and construction and application thereof. The application verifies the role and mechanism of THEMIS in maintaining the long-term killing of tumor cells of CAR-T through experiments. The CAR-T cell overexpressing THEMIS is constructed, compared with a control group, the proliferation capacity and memory cell formation capacity of the THEMIS-7x19 CAR-T cell are enhanced after antigen stimulation, and the cytokines are in a controllable state, the cell apoptosis and exhaustion are reduced, and the long-term tumor killing capacity can be maintained more effectively. The in-vivo experiment also proves that the THEMIS-7x19 CAR-T cell has stronger anti-tumor effect compared with the control group in a lymphoma tumor-bearing mouse model, and the survival time of the mouse is significantly prolonged.

The application provides a kind of nano preparation with antioxidant function and the use for treating glaucoma, the preparation is composed of oil phase and water phase.Oil phase is lecithin, medium-chain triglyceride, fat-soluble antioxidant, glaucoma treatment drug, water phase is water-soluble antioxidant or deionized water.The nano delivery system described in the application is by loading glaucoma treatment drug in the nano preparation containing antioxidant, can improve local drug concentration, prolong drug retention time, at the same time, through antioxidant scavenging excess active oxygen, reduce inflammatory response, reduce eye cell apoptosis, so as to achieve good therapeutic effect.The nano preparation described in the application can be nano emulsion, liposome, micelle or lipid nanoparticle and other drug delivery systems.The nano preparation can deliver therapeutic drugs while scavenging ROS, reducing eye inflammation and reducing cell apoptosis to achieve more efficient therapeutic effect, with the characteristics of double effect, easy to produce and prepare, wide application range, etc.

The invention belongs to the technical field of cosmetics, and particularly relates to a natural-source composition with ultraviolet absorption and ultraviolet conversion functions and application of the natural-source composition in cosmetics. The natural source composition provided by the invention comprises a honeysuckle flower extract, a butterflybush flower and leaf extract and a spirulina platensis extract, wherein the mass ratio of the honeysuckle flower extract to the butterflybush flower and leaf extract to the spirulina platensis extract is (5-30): (1-20): (0.01-10). The natural-source composition provided by the invention not only can effectively absorb UVC, UVB and UVA full-wave band ultraviolet light, but also can convert the ultraviolet light into red light beneficial to a human body, so that the effects of resisting inflammation, repairing, fading red light, resisting light damage and resisting light aging are achieved. The natural-source composition provided by the invention is applied to cosmetics and can play a role in sunscreen and synergism. Meanwhile, the composition provided by the invention is natural, green, high in safety, mild and non-irritant, and can be used for children and people with sensitive skin.

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.

The invention discloses a nutritional composition for fatty liver and liver protection and a preparation method thereof, and relates to the technical field of nutritional health-care product preparation. The preparation method comprises the following steps: mixing fat-soluble components such as an elephantopus scaber alcohol extract with hydroxylated modified soybean phospholipid, and adding absolute ethyl alcohol to prepare a hydrophobic phase solution; deionized water is added into water-soluble components such as the walnut oligopeptide to prepare a hydrophilic phase solution; dropwise adding the hydrophobic phase solution into the hydrophilic phase solution, and performing high-shear stirring, intermittent ultrasonic emulsification, curing and spray drying to prepare a nano composite carrier; mixing with hippocampal peptide and ganoderan, and constructing a gradient release structure through double-layer hydroxypropyl methyl cellulose coating; and finally adding the remaining components and mixing to prepare the uniformly mixed material for tabletting. Multi-component synergistic lipid lowering, hepatocyte repairing and anti-oxidation and anti-inflammatory effects are adopted, the bioavailability is improved by matching with the nano-carrier and a gradient release technology, the liver protection and lipid lowering effects are remarkable, the storage stability is high, and the composition is suitable for long-term conditioning of people with fatty liver.

This invention belongs to the field of functional microbial technology, specifically relating to a fermented *Lactobacillus rimoxifer* and its application in anti-aging. The fermented *Lactobacillus rimoxifer* F-B9-1-2 and its culture provided by this invention exhibit significant in vitro antioxidant capacity. A 0.5 mg / mL culture showed a scavenging rate of 89.3±2.1% for ABTS free radicals, demonstrating its antioxidant efficacy by reducing free radical damage to cells and maintaining normal cell function. Furthermore, treatment with its culture reduced the SA-β-gal positive cell rate from 12.8% to 7.1%, exhibiting good in vivo antioxidant activity, thus helping to inhibit or alleviate the aging process.

The invention discloses a preparation BMSCs-sec for repairing scar uterus and a preparation method thereof.The preparation method comprises the steps that primary BMSCs growing well are subcultured to the third generation, and BMSC cells are collected; the method comprises the following steps: inoculating BMSCs into a culture bottle, culturing in a complete culture medium, when the cell adhesion fusion rate reaches 80%, discarding the supernatant, cleaning cells with PBS, adding DMEM / F12, culturing, collecting the cell supernatant, centrifuging, removing cell debris and dead cells, filtering with a filter, and collecting the filtrate; and transferring the filtrate into an ultrafiltration tube, and centrifuging to obtain a concentrated cell supernatant, thereby obtaining the preparation BMSCs-sec. The prepared preparation BMSCs-sec is used for repairing the scar uterus, and a new thought is provided for treating the uterus scar injury by using cell secretions.

This invention belongs to the field of regenerative medicine technology, specifically relating to bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1, their preparation method, and applications. The steps are as follows: Primary mouse bone marrow mononuclear precursor cells are cultured in expansion medium for 7 days to obtain macrophages, with the medium changed every 2-3 days during this period; on the 7th day, the expansion medium is replaced with a high-efficiency induction medium and cultured for 46-50 hours to obtain bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1. This invention, through a time-series strategy of TGF-β pre-induction combined with IL-4 / IL-5 / IL-13 synergistic induction, can significantly enhance the expression levels of CD301b, TIMD4, and LYVE-1 in BMDM, making their function close to that of natural cardiac resident macrophages, and effectively exerting anti-inflammatory, repair-promoting, and ventricular remodeling-inhibiting effects after AMI.

The application provides a serum-free cryopreservation solution and application thereof in cell cryopreservation. The serum-free cryopreservation solution comprises a first additive, a saccharide, an inorganic salt, a protein and a second additive; in the serum-free cryopreservation solution, the mass concentration of the first additive is 0.2-15% (w / v), the concentration of the saccharide is 2-15 mg / mL, the mass concentration of the inorganic salt is 0.7-1.2% (w / v), the concentration of the protein is 0.05-0.5 g / mL, and the concentration of the second additive is 0.5-5 mg / mL. The serum-free cryopreservation solution provided by the application ensures that the cell still has high survival rate, high activity and functional integrity after cryopreservation through the combined action of the above components, the composition of the cryopreservation solution is clear, and no animal-derived serum needs to be added, so that the immunogenicity risk, pathogen contamination and batch difference caused by the animal-derived serum are avoided, and the safety of the cryopreservation solution is significantly improved.

The application relates to a kind of nanoparticles based on polyphenol compound modification and its preparation and application.The nanoparticles are mainly Cu 2‑x Se (0<=x<=1) nanoparticles, the surface is modified using polyphenol compounds, and nanoparticles with antioxidant protection are obtained by reasonable use of different surface modifiers.The preparation method can obtain nanoparticles with adjustable size, good water dispersibility, good biocompatibility and strong antioxidant effect.The application also discloses the application of nanoparticles after different modifications as new antioxidants, effective removal of reactive oxygen species (ROS), protection of neuronal cell damage and improvement of ischemia-reperfusion injury.

This invention discloses the use of *Physalis alkekengi* oil in the preparation of drugs for the prevention and / or treatment of neurodegenerative diseases, belonging to the field of biomedical technology. The *Physalis alkekengi* oil of this invention is obtained by supercritical CO2 extraction, containing 2.16 g / 100g of EPA, 0.0104 g / 100g of nervonic acid, and a total unsaturated fatty acid content of 49.1 g / 100g. *Physalis alkekengi* oil exerts neuroprotective effects through multiple pathways, including inhibiting β-amyloid protein deposition, reducing neuronal apoptosis, alleviating neuroinflammation, and protecting dopaminergic neurons. It can effectively counteract neuronal damage caused by excitotoxicity and oxidative stress, significantly improve spatial learning and memory abilities, and alleviate cognitive decline. This invention provides a highly efficient and safe drug option for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

The application provides an application of tRF-22 in preparation of a drug for delaying ovarian aging, and a nucleotide sequence of the tRF-22 is TTATTCGACTCCTGGCTGGGC. Through in-vivo and in-vitro experiments, it is proved that the tRF-22 can improve the degeneration of the aging ovarian tissue, reduce the expression of the aging marker, inhibit the secretion of the SASP factor, reverse the aging phenotype of the human ovarian granulosa cell, improve the proliferation activity, relieve the cycle arrest, reduce the apoptosis and the accumulation of the active oxygen. Mechanism research shows that the tRF-22 can inhibit the expression of BNIP3, repair the damage of the mitochondrial ultrastructure, restore the mitochondrial autophagy flux, improve the membrane potential, the ATP level and the oxygen consumption rate, and reshape the mitochondrial homeostasis. The application provides a new active molecule and an action target for the nucleic acid drug for delaying ovarian aging.